News

Isaacs and Bellini discuss the highlights of the Endocrine Society’s annual meeting, from upcoming treatments to public education.

Patients with hereditary angioedema who switched to donidalorsen saw significantly fewer attacks and improved disease control. The FDA decision expected in August 2025.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.

In this interview segment, Hamade highlights the potential benefits of an oral drug like deucravacitinib in psoriasis and psoriatic arthritis.

A 2-step direct amoxicillin challenge safely ruled out penicillin allergy in low-risk pregnant patients, offering a faster alternative to skin testing.

An audio recap of the top 5 stories in healthcare news from the week of 07/07-07/13.

This analysis examined the connection between atopic dermatitis severity and frequency of flares, along with which variables potentially predict flares.

Psychiatrists at the 2025 So Cal Psych Conference shared evidence-based tools and therapies to improve mental health outcomes for new mothers.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and designations as well as new clinical trial data, in this week's essential news roundup.

Steger discussed the importance of tailoring diet strategies to patients with type 2 diabetes.

Shah discusses the stagnation of the T1D treatment landscape and the potential progress that GLP-1 RA research could present.

This interview with Hamade highlights some of the most notable takeaways regarding deucravacitinib’s safety among patients with psoriasis.

Host Brendon Neuen is joined by guests Tor Biering-Sørensen and Kristoffer Skaarup to discuss NUDGE-CKD and implementation trial design.

Announced by Aldeyra Therapeutics, Inc. on July 17, the FDA also assigned a PDUFA target action date of December 16, 2025.

Philis-Tsimikas emphasized the impact of nonmedical factors on health and how clinicians can be cognizant of them in their patient management.

Shah discusses the results from the ADJUST-T1D trial comparing semaglutide to placebo, which saw a significant disparity in semaglutide’s favor.

In this Q&A, Alva discusses how to identify tardive dyskinesia, approaches for treatment-resistant depression, and emerging therapies.

The most effective FMT strategy involved giving FMT as multiple-dose capsules or colonoscopy after an extended period of antibiotic pretreatment.

Endeavor BioMedicines' Taladegib gains orphan drug status for idiopathic pulmonary fibrosis, showing promise in improving lung function and patient outcomes.

In a new study, Yale researchers develop a method that has the potential to cure cystic fibrosis prior to birth.

Join leading experts at the 42nd Annual Echocardiography and Structural Heart Symposium to explore cutting-edge advancements in cardiovascular care.

A clinician performing an echocardiogram of a patient's heart

The Yale Biomedical Imaging Institute will drive transformative advancements in both basic science and clinical translation.

This analysis highlights differences between topical and oral finasteride for hair loss, specifically looking at adverse events and any causal connections.

Yale researchers developed an AI model that illuminates critical details about—and possible treatments for—idiopathic pulmonary fibrosis. It could do so for many other diseases.

At 2025 So Cal Psych, Maguire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.

Neffy showed fast symptom resolution in children experiencing moderate anaphylaxis following oral food challenges, offering a needle-free alternative to epinephrine injection.

Isaacs and Bellini discuss 3 more of the most impactful trials presented at the 85th annual American Diabetes Association conference in part 2 of this 2-part recap.